Email Updates

Search form

You are here

Hormonal Contraception and HIV Risk: Understanding the ECHO trial

April 2, 2019

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.

Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.

The webinar featured:

  • Beth Schlachter, Executive Director, FP2020
  • Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
  • Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
  • Tamar Abrams, Communications Director, FP2020

You can view the webinar recording below.